Step forward in early recognition of systemic sclerosis: data from the Leiden CCISS cohort

Autor: Philippine Kiès, Liesbeth J J Beaart-van de Voorde, Maarten K Ninaber, Maarten E Tushuizen, Anja Corsel, Talitha Dhondai, J J Miranda Geelhoed-Veltman, Marlies E Heuvers

Publikováno v: RMD Open, Vol 9, Iss 2 (2023)

Background Since 2009, Dutch patients with a confirmed diagnosis/suspicion of systemic sclerosis (SSc) can be referred to the Leiden Combined Care in Systemic Sclerosis (CCISS) cohort. This study evaluated whether early recognition of SSc has improve

Externí odkaz: https://doaj.org/article/fd84ee86a96c49fb8571f0ad6a188a2a

Optimizing quality of life in patients with idiopathic pulmonary fibrosis

Autor: Mirjam J. G. van Manen, J. J. Miranda. Geelhoed, Nelleke C. Tak, Marlies S. Wijsenbeek

Publikováno v: Therapeutic Advances in Respiratory Disease, Vol 11 (2017)

Idiopathic pulmonary fibrosis (IPF) is a devastating, progressive and ultimately fatal lung disease. The combination of poor prognosis, uncertainty of disease course and severe symptom burden heavily impacts patients’ and their families’ quality

Externí odkaz: https://doaj.org/article/08a649b547a74a97b99a83c31db26851

Home monitoring of lung function, symptoms and quality of life after admission with COVID-19 infection: The HOMECOMIN' study

Autor: Gizal Nakshbandi, Catharina C. Moor, Esther J. Nossent, J. J. Miranda Geelhoed, Sara J. Baart, Bart G. Boerrigter, Joachim G. J. V. Aerts, Suzan F. M. Nijman, Helger Y. Santema, Merel E. Hellemons, Marlies S. Wijsenbeek

Publikováno v: Respirology, 27(7), 501-509. Wiley-Blackwell Publishing Ltd
Nakshbandi, G, Moor, C C, Nossent, E J, Geelhoed, J J M, Baart, S J, Boerrigter, B G, Aerts, J G J V, Nijman, S F M, Santema, H Y, Hellemons, M E & Wijsenbeek, M S 2022, ' Home monitoring of lung function, symptoms and quality of life after admission with COVID-19 infection : The HOMECOMIN' study ', Respirology, vol. 27, no. 7, pp. 501-509 . https://doi.org/10.1111/resp.14262
Respirology, 27(7), 501-509. Wiley-Blackwell
Respirology, 27(7), 501-509. WILEY

Background and objective: To develop targeted and efficient follow-up programmes for patients hospitalized with coronavirus disease 2019 (COVID-19), structured and detailed insights in recovery trajectory are required. We aimed to gain detailed insig

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae88c5a1b8ffeab7a3de93ce62357ceb
https://pubmed.ncbi.nlm.nih.gov/35441433

Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial

Autor: Job J.M.H. van Bragt, Michiel Alexander de Raaf, Harm Jan Bogaard, Pierre M Bet, Azar Kianzad, Merlijn Reijrink, Esther J. Nossent, Job R Schippers, Lucas R Celant, Lieuwe D. J. Bos, Jeroen N. Wessels, Mirte Muller, Chris Happé, Niels Pronk, Anton Vonk Noordegraaf, Leo M. A. Heunks, Liza Botros, E Marleen Kemper, Wim Boersma, Michel van den Heuvel, Hans P Grotjohan, Rianne J A Hoek, Carolina C Pamplona, Sara Azhang, Nicole P. Juffermans, Marry R Smit, Ivo van der Lee, Imke H Bartelink, Bas F M van Raaij, Janneke E Stalenhoef, Wouter Hoefsloot, Pieter R. Tuinman, Ariana Lammers, Katrien Eger, Boaz D Hazes, E Laurien van der Lee, Karin A T Boomars, Arthur L E M Vanhove, Frances S. de Man, Laura A Hagens, Anke-Hilse Maitland-van der Zee, Elisabeth C W Neefjes, Marcus J. Schultz, Pearl F M Mau Asam, Erik Duijvelaar, Patrick J Smeele, A. Josien Smits, Frank W J M Smeenk, Elise M A Slob, Laurien M A Oswald, Ary Serpa Neto, J. J. Miranda Geelhoed, Jessie Van Wezenbeek, Gert-Jan Braunstahl, Herman M A Hofstee, Romke Hoekstra, Peter I. Bonta, Jurjan Aman, Nienke Paternotte, Renate Kos, Ahmed A. Bayoumy, Peter W A Kunst, Maria J Overbeek, Adinda Mieras, Yurika L E van Glabbeek

Publikováno v: lancet. Respiratory medicine, 9(9), 957-968. Elsevier Limited
The Lancet Respiratory Medicine, 9(9), 957-968. ELSEVIER SCI LTD
The Lancet Respiratory Medicine, 9(9), 957-968. Elsevier Ltd.
Lancet Respiratory Medicine, 9, 957-968
Aman, J, Duijvelaar, E, Botros, L, Kianzad, A, Schippers, J R, Smeele, P J, Azhang, S, Bartelink, I H, Bayoumy, A A, Bet, P M, Boersma, W, Bonta, P I, Boomars, K A T, Bos, L D J, van Bragt, J J M H, Braunstahl, G-J, Celant, L R, Eger, K A B, Geelhoed, J J M, van Glabbeek, Y L E, Grotjohan, H P, Hagens, L A, Happe, C M, Hazes, B D, Heunks, L M A, van den Heuvel, M, Hoefsloot, W, Hoek, R J A, Hoekstra, R, Hofstee, H M A, Juffermans, N P, Kemper, E M, Kos, R, Kunst, P W A, Lammers, A, van der Lee, I, van der Lee, E L, Maitland-van der Zee, A-H, Mau Asam, P F M, Mieras, A, Muller, M, Neefjes, L, Nossent, E J, Oswald, L M A, Overbeek, M J, Pamplona, C, Paternotte, N, Pronk, N, de Raaf, M A, van Raaij, B F M, Reijrink, M, Schultz, M J, Serpa Neto, A, Slob, E M, Smeenk, F W J M, Smit, M R, Smits, A J, Stalenhoef, J E, Tuinman, P R, Vanhove, A L E M, Wessels, J N, van Wezenbeek, J C C, Vonk Noordegraaf, A, de Man, F S & Bogaard, H J 2021, ' Imatinib in patients with severe COVID-19 : a randomised, double-blind, placebo-controlled, clinical trial ', Lancet respiratory medicine, vol. 9, no. 9, pp. 957-968 . https://doi.org/10.1016/S2213-2600(21)00237-X
The Lancet. Respiratory Medicine
Lancet respiratory medicine, 9(9), 957-968. Elsevier Limited
Lancet Respiratory Medicine, 9, 9, pp. 957-968
The Lancet Respiratory Medicine

Background The major complication of COVID-19 is hypoxaemic respiratory failure from capillary leak and alveolar oedema. Experimental and early clinical data suggest that the tyrosine-kinase inhibitor imatinib reverses pulmonary capillary leak. Metho

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95b9388602de3565960dbc68949c8a0a
https://pure.amc.nl/en/publications/imatinib-in-patients-with-severe-covid19(40a385b0-de53-45cd-aff2-cb6b5cdfc6d3).html

Optimizing quality of life in patients with idiopathic pulmonary fibrosis

Autor: J. J. Miranda Geelhoed, Mirjam J.G. van Manen, Marlies S. Wijsenbeek, Nelleke C. Tak

Publikováno v: Therapeutic Advances in Respiratory Disease, 11(3), 157-169. SAGE Publications Ltd
Therapeutic Advances in Respiratory Disease, Vol 11 (2017)

Idiopathic pulmonary fibrosis (IPF) is a devastating, progressive and ultimately fatal lung disease. The combination of poor prognosis, uncertainty of disease course and severe symptom burden heavily impacts patients’ and their families’ quality

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67dbc5f93a6e420a4f4157e909a58a5c
https://doi.org/10.1177/1753465816686743